Skip to main content
Clinical Trials/ITMCTR2100004821
ITMCTR2100004821
Recruiting
Phase 4

Efficacy and safety of Wuling capsule in the treatment of early Parkinson's disease with mild depression: a multicenter, randomized, double-blind, placebo-controlled study

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Xinhua Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients aged 45 to 80 years with primary Parkinson's disease, regardless of gender;
  • 2\.Hoehn\-Yahr grading \< 3 at the onstage;
  • 3\.MMSE \>\= 24 points;
  • 4\.Accompanied with depressive symptoms (8 \<\= HAMD17 \< 18\);
  • 5\.Stable basic treatment for Parkinson's disease;
  • 6\.Sign informed consent.

Exclusion Criteria

  • 1\.Other nervous system diseases, mental diseases and serious physical diseases;
  • 2\.History of alcohol and drug dependence;
  • 3\.Dementia patients;
  • 4\.High risk of suicide or suicide attempt within 6 months (HAMD\-17 item 3 \>\= 3 points);
  • 5\.Antidepressant treatment or other psychotic treatment in the past month;
  • 7\.Those who participated in other clinical trials in recent 3 months;
  • 8\.Pregnant or lactating women;
  • 9\.Patients considered unsuitable for the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials